Abstract
In the human brain several cell types are capable of initiating and amplifying a brain specific inflammatory response involving the synthesis of cytokines, prostaglandins and oxygen free radicals. In Alzheimers disease (AD), signs of an inflammatory activation of microglia and astroglia are present inside and outside amyloid deposits. Cell culture and animal models suggest an interactive relationship between inflammatory activation, reduced neuronal functioning and deposition of amyloid. The activation of inflammation-associated enzymes such as p38 mitogen-activated protein kinase (p38 MAPK) and cycloxygenase-2 (COX-2) is not restricted to glial cells but also found in neurons and may contribute to intraneuronal damage. Epidemiological studies have shown a reduced risk of AD among users of anti-inflammatory drugs. Therefore, anti-inflammatory drugs have become the focus of several new treatment strategies. Small clinical trials with non-steroidal anti-inflammatory drugs (NSAIDs) such as indomethacin and diclofenac showed a trend for a disease modifying effect, while clinical trials with steroids did not show a beneficial effect. NSAIDs may not only act on COX-2 but also inhibit COX-1 activity or activate peroxisome proliferator-activated receptor gamma (PPARγ. Among promising new strategies to reduce the inflammatory activation in the CNS interfering with intracellular pro-inflammatory pathways has been shown to be effective in various cell culture and animal models. Inhibitors of p38MAPK and PPARγ agonists may be suitable agents to suppress inflammatory activation in AD.
Keywords: Alzheimers Disease, Microglia, Astroglia, p38 mitogen-activated protein kinase (p38 MAPK), cycloxygenase-2 (COX-2), non-steroidal anti-inflammatory drugs (NSAIDs), peroxisome proliferator-activated receptor, anti-inflammatory drugs
Current Medicinal Chemistry
Title: Pathways of Inflammatory Activation in Alzheimers Disease: Potential Targets for Disease Modifying Drugs
Volume: 9 Issue: 1
Author(s): M. Hull, K. Lieb and B. L. Fiebich
Affiliation:
Keywords: Alzheimers Disease, Microglia, Astroglia, p38 mitogen-activated protein kinase (p38 MAPK), cycloxygenase-2 (COX-2), non-steroidal anti-inflammatory drugs (NSAIDs), peroxisome proliferator-activated receptor, anti-inflammatory drugs
Abstract: In the human brain several cell types are capable of initiating and amplifying a brain specific inflammatory response involving the synthesis of cytokines, prostaglandins and oxygen free radicals. In Alzheimers disease (AD), signs of an inflammatory activation of microglia and astroglia are present inside and outside amyloid deposits. Cell culture and animal models suggest an interactive relationship between inflammatory activation, reduced neuronal functioning and deposition of amyloid. The activation of inflammation-associated enzymes such as p38 mitogen-activated protein kinase (p38 MAPK) and cycloxygenase-2 (COX-2) is not restricted to glial cells but also found in neurons and may contribute to intraneuronal damage. Epidemiological studies have shown a reduced risk of AD among users of anti-inflammatory drugs. Therefore, anti-inflammatory drugs have become the focus of several new treatment strategies. Small clinical trials with non-steroidal anti-inflammatory drugs (NSAIDs) such as indomethacin and diclofenac showed a trend for a disease modifying effect, while clinical trials with steroids did not show a beneficial effect. NSAIDs may not only act on COX-2 but also inhibit COX-1 activity or activate peroxisome proliferator-activated receptor gamma (PPARγ. Among promising new strategies to reduce the inflammatory activation in the CNS interfering with intracellular pro-inflammatory pathways has been shown to be effective in various cell culture and animal models. Inhibitors of p38MAPK and PPARγ agonists may be suitable agents to suppress inflammatory activation in AD.
Export Options
About this article
Cite this article as:
Hull M., Lieb K. and Fiebich L. B., Pathways of Inflammatory Activation in Alzheimers Disease: Potential Targets for Disease Modifying Drugs, Current Medicinal Chemistry 2002; 9 (1) . https://dx.doi.org/10.2174/0929867023371292
DOI https://dx.doi.org/10.2174/0929867023371292 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Mutual Interaction Between Sleep and Epilepsy on the Neurobiological Basis and Therapy
Current Neuropharmacology Subject Index To Volume 7
Current Pharmaceutical Design The Role of Vascular Endothelial Growth Factor Gene as the Genetic Marker of Atherothrombotic Disorders and in the Gene Therapy of Coronary Artery Disease
Cardiovascular & Hematological Agents in Medicinal Chemistry Advances in Interleukin-12 Gene Therapy for Acquired Liver Diseases
Current Gene Therapy In Vivo Space Radiation-Induced Non-Targeted Responses: Late Effects on Molecular Signaling in Mitochondria
Current Molecular Pharmacology Granulocyte Colony-stimulating Factor as the Expecting Sword for the Treatment of Severe Sepsis
Current Pharmaceutical Design Subacute Thyroiditis Post-COVID-19 Infection: A Case Report
New Emirates Medical Journal Transforming Growth Factor-β, Cell Signaling and Cardiovascular Disorders
Current Vascular Pharmacology Biomedical Exploitation of Self Assembled Peptide Based Nanostructures
Current Protein & Peptide Science Functionalization of Non-Activated C-H Bonds in the Synthesis of Vitamin D Metabolites and Analogs
Current Topics in Medicinal Chemistry Metabotropic Glutamate Receptors as Targets for Analgesia: Antagonism, Activation, and Allosteric Modulation
Current Pharmaceutical Biotechnology RNA Interference as Therapeutics for Hepatocellular Carcinoma
Recent Patents on Anti-Cancer Drug Discovery TGF-Beta Type I Receptor (Alk5) Kinase Inhibitors in Oncology
Current Pharmaceutical Biotechnology Selective Elevation of Circulating CCL2/MCP1 Levels in Patients with Longstanding Post-vaccinal Macrophagic Myofasciitis and ASIA
Current Medicinal Chemistry Graphical Abstracts:
Current Angiogenesis (Discontinued) Meet Our Editorial Board Member
Current Neuropharmacology Patent Analysis as a Tool for Research Planning: Study on Natural Based Therapeutics Against Cancer Stem Cells
Recent Patents on Anti-Cancer Drug Discovery Development of IL-5 Receptor Antagonists
Current Pharmaceutical Design Macrophages in Inflammation
Current Drug Targets - Inflammation & Allergy Metabolic-Inflammatory Changes, and Accelerated Atherosclerosis in HIV Patients: Rationale for Preventative Measures
Current Medicinal Chemistry